Abstract
Twenty-eight patients with advanced adenocarcinoma of the breast were treated with a combination of VP-16 and adriamycin (VAD). Two complete (CR), and eight partial (PR) remissions were observed. The CR plus PR produced a 36% response rate in this study. Nine additional patients had stable disease for at least 2 months. No drug deaths were seen with this combination, but thrombocytopenia, leukopenia, and vomiting were observed. Alopecia was seen in 100% of the patients treated with the above combination. This study suggests that the combination of adriamycin and VP-16 may be a good second-line therapy for patients with adenocarcinoma of the breast who failed and/or relapsed to CMFVP.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Alopecia / chemically induced
-
Antineoplastic Combined Chemotherapy Protocols*
-
Breast Neoplasms / drug therapy*
-
Cyclophosphamide / administration & dosage
-
Dexamethasone
-
Doxorubicin / administration & dosage*
-
Doxorubicin / adverse effects
-
Drug Therapy, Combination
-
Etoposide / administration & dosage*
-
Etoposide / adverse effects
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Leukopenia / chemically induced
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Podophyllotoxin / analogs & derivatives*
-
Prednisone / administration & dosage
-
Thrombocytopenia / chemically induced
-
Vincristine / administration & dosage
-
Vomiting / chemically induced
Substances
-
Vincristine
-
Etoposide
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Podophyllotoxin
-
Fluorouracil
-
Prednisone
-
Methotrexate
Supplementary concepts
-
CMFVP protocol
-
VAD protocol